Amneal Pharmaceuticals Reprices Term Loan, Securing $11M in Annual Interest Savings
AMRX has more than doubled off its 52-week low of $6.685.
Summary
Amneal Pharmaceuticals amended its term loan credit agreement, reducing interest rate margins by 50 basis points, which is projected to save the company $11 million annually in cash interest expenses.
Key Events · Financing and Capital Events · AMRX
-
Term Loan Repricing
Amneal Pharmaceuticals LLC, a subsidiary, entered into Amendment No. 2 to its Term Loan Credit Agreement, dated February 2, 2026. This repricing converted existing term loans into new term loans totaling approximately $1.96 billion and incurred an additional new term loan of approximately $134.7 million.
-
Interest Rate Reduction
The amendment reduces the applicable interest rate margin on the new term loans by 50 basis points (0.50%), setting it at 2.00% for base rate loans and 3.00% for secured overnight financing rate (SOFR) loans.
-
Annualized Cash Interest Savings
The company estimates that this repricing will result in approximately $11 million in annualized cash interest expense savings compared to the previous credit agreement.
-
Maturity Date Unchanged
The maturity date of the term loans, August 1, 2032, remains unchanged by this amendment.
Analysis · AMRX · Life Sciences
Amneal Pharmaceuticals has successfully repriced its existing term loan, reducing the interest rate margin by 50 basis points. This proactive financial management move is expected to generate approximately $11 million in annualized cash interest expense savings. The transaction converts existing term loans and incurs a new term loan, maintaining the original maturity date. This positive development enhances the company's financial flexibility and cash flow, building on recent positive news regarding its opioid settlement and strong financial guidance, and comes as the stock trades near its 52-week high.
At the time of this filing, AMRX was trading at $14.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $6.69 to $15.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.